SOUTH SAN FRANCISCO, Calif. — Mirvie has announced the launch of Encompass™, a breakthrough solution designed to predict and help prevent preeclampsia—one of the most common and serious pregnancy complications. The tool combines a novel RNA-based blood test with a personalized action plan and virtual support, aiming to transform prenatal care from reactive to predictive and preventive.
Preeclampsia affects roughly 1 in 12 pregnancies in the U.S., with rates continuing to rise. Despite the availability of effective preventive strategies, such as low-dose aspirin and enhanced monitoring, there has historically been no reliable way to identify at-risk pregnancies early. As a result, prenatal care has often relied on observing symptoms once the condition is already progressing, leading to low adherence to preventive interventions and a reactive approach to care.
Mirvie’s Encompass platform is powered by its proprietary RNA technology, which analyzes cell-free RNA in maternal blood to assess placental health and predict the likelihood of developing preterm preeclampsia. Based on data from nearly 11,000 pregnancies across the U.S., the test correctly identified 90% of pregnancies that later developed preterm preeclampsia as high-risk. A low-risk result correlates with a 99.7% chance of avoiding the condition.
“For too long, prenatal care has been stuck in a model that hasn’t evolved with advances in precision medicine,” said Maneesh Jain, CEO and Co-Founder of Mirvie. “With Encompass, we’re helping usher in a new era of proactive care, offering expecting families real insights early enough to make a meaningful difference.”
The Encompass experience is designed to be consumer-friendly and fully digital. Expecting mothers aged 35 and older without pre-existing high-risk factors can purchase the test online. After a telehealth consultation and mobile phlebotomy appointment, results are delivered within 10 to 14 days. The launch also includes efforts to expand access through healthcare providers, maternal health benefits platforms, and insurance payers.
Dr. Thomas McElrath, Mirvie’s Vice President of Clinical Development and a maternal-fetal medicine physician at Brigham and Women’s Hospital, emphasized that Encompass addresses a longstanding gap in prenatal care. “The standard prenatal model was developed nearly a century ago and remains largely unchanged,” he said. “By giving patients information about their preeclampsia risk months before symptoms emerge, we can take informed, preventive steps that reduce complications and improve outcomes.”
Encompass also includes a responsive virtual assistant to guide patients through personalized prevention strategies, such as aspirin adherence, home blood pressure monitoring, and more frequent check-ins with care teams. The solution reflects growing consumer demand for personalized healthcare and seeks to ease pressure on OB/GYN practices strained by increasing maternal health challenges.
“With Encompass, we’re not just improving care—we’re also enhancing the clinical workflow,” said Aimee Corso, Senior Vice President of Growth at Mirvie. “Expecting mothers are looking for clarity, and physicians need better tools to deliver personalized care efficiently. This launch is a step forward for both.”
The Encompass rollout represents a significant milestone in Mirvie’s broader mission to leverage biology and technology to improve women’s health outcomes. As the company scales access across the U.S., it aims to reshape the standard of prenatal care—starting with preeclampsia, but ultimately reaching across a spectrum of pregnancy complications.
